Selpercatinib and pralsetinib, two highly selective inhibitors of RET kinase, have been recently approved by the FDA for use in NSCLC patients with RET mutations (51, 52) and have both shown robust intracranial activity in patients with BrM (53, 54). The gene discussed is RET; the disease is non-small cell lung carcinoma.